I-693 Prep: MenACWY vs MenB: Who Needs the 11–12 Dose and 16 Booster
MenACWY protects against meningococcal serogroups A, C, W, and Y, while MenB covers only serogroup B, and the two are not interchangeable or redundant. Most adolescents need a routine MenACWY dose at 11 to 12 with a booster at 16, and college-bound teens and young adults should also talk to their clinician about MenB. If your teen is heading to a dorm this fall, checking both records now avoids a scramble later.
TL;DR:
- MenACWY provides broader protection by covering serogroups A, C, W, and Y, and is recommended routinely for adolescents at ages 11 to 12 with a booster at 16.
- MenB protection lasts only one to two years and is offered through shared decision-making based on individual risk factors or residence in shared housing like college dorms.
- Two combination vaccines, Penbraya and Penmenvy, exist for simultaneous protection against both MenACWY and MenB, but they are only clinically indicated when both serogroups are relevant.
- Most adolescents receive MenACWY as part of their routine schedule, while MenB is a selective, on-demand choice influenced by outbreak exposure and personal health conditions.
- Vaccination reactions are usually mild, including arm soreness and fatigue, but recipients should wait briefly after injection due to the rare risk of severe allergic reactions.
Table of Contents
- MenACWY vs. MenB at a glance
- Who needs MenACWY and when to get it
- MenB and how shared clinical decision-making works
- How long protection lasts and when boosters matter
- Side effects, safety, and when to check with a doctor
- Combination vaccines and getting both at once
- What this means for your I-693 vaccination review
- Balancing population protection with individual choice
- Getting your vaccine records in order before your immigration exam
- Sources
- FAQ
MenACWY vs. MenB at a glance
The two vaccines target different strains of the same bacterium, Neisseria meningitidis, and the U.S. vaccination program treats them very differently. MenACWY is a routine, universally recommended adolescent vaccine because serogroups A, C, W, and Y cause disease across the general population. MenB is handled through individualized conversation rather than a blanket mandate, since serogroup B tends to cluster in specific settings like college housing and outbreaks.
- MenACWY covers serogroups A, C, W, and Y and is part of the routine adolescent schedule.
- MenB covers only serogroup B and is offered through shared clinical decision-making for most healthy teens.
- Pentavalent options like Penbraya and Penmenvy cover both sets of serogroups (A, B, C, W, Y) in a single formulation when both vaccines are indicated at once, according to the FDA’s approval information.
Neither vaccine substitutes for the other, and a teen who only receives MenACWY still has no protection against serogroup B disease.
Who needs MenACWY and when to get it
MenACWY is routinely recommended at age 11 to 12, with a booster dose at 16, to cover the years when meningococcal risk climbs and early protection has started to fade, according to CDC’s meningococcal vaccine recommendations. That booster timing matters because many college students move into dorms shortly after their 16-year-old dose would have been given, and skipping it leaves a gap right when exposure risk rises.
Certain groups need MenACWY on an accelerated or expanded schedule regardless of age:
- Military recruits and people with asplenia or complement deficiency.
- Travelers to regions where meningococcal disease is endemic.
- First-year college students moving into residence halls who have not had a dose since age 16.
Three MenACWY vaccines are licensed in the United States: Menactra, Menveo, and MenQuadfi. Each is approved for use in adolescents and adults, and a clinician can check which one a patient previously received before recommending a booster.
MenB and how shared clinical decision-making works
Because MenB protection is shorter-lived and serogroup B disease is less common overall, CDC frames the MenB decision as a conversation rather than a routine mandate. The shared clinical decision-making guidance recommends this approach for healthy 16 to 23-year-olds, while people age 10 and older with certain medical risk factors should receive MenB routinely.
A useful pre-college visit walks through a short list of practical questions:
- Will the student live in a dorm or other shared housing with frequent close contact?
- Does the student have a condition like asplenia or complement deficiency that raises baseline risk?
- Is there a known outbreak at the school or in the surrounding community?
- Does the family want faster protection through an accelerated schedule?
MenB is typically given as a 2-dose series spaced six months apart, though a 3-dose option exists for people who need faster protection. Two brands are licensed: Bexsero and Trumenba, and they are not interchangeable, so a series started with one must be completed with the same product.
How long protection lasts and when boosters matter
MenACWY protection wanes over several years, which is the reason ACIP built a booster into the adolescent schedule rather than relying on the single dose given at 11 or 12. MenB protection tends to fade faster, often within one to two years, according to CDC’s shared clinical decision-making guidance, so people who remain at elevated risk, such as those with ongoing outbreak exposure, may need a booster sooner than a MenACWY recipient would.
During real outbreaks, health departments have used MenB with first-dose coverage ranging from 14% to 98%, with a median of 67%, across ten university outbreaks in seven states between 2013 and 2018. That range shows how much campaign intensity and local response can vary even when the underlying vaccine and dosing schedule stay the same.
Side effects, safety, and when to check with a doctor
Both vaccines produce the reactions typical of most adolescent shots: soreness at the injection site, mild fatigue, headache, and sometimes a low fever for a day or two. These usually resolve within 48 to 72 hours without treatment.
- Common reactions: arm soreness, redness, mild fever, and fatigue in the first day or two.
- Rare but serious events: severe allergic reaction (anaphylaxis) has occurred and typically appears within minutes of the shot, which is why patients wait briefly on-site after vaccination.
- Contraindications: a severe allergic reaction to a previous dose or to any vaccine component rules out that specific product.
- Pregnancy: patients who are pregnant should discuss timing with their provider before either vaccine.
Pro Tip: Keep a photo of your vaccination card on your phone. Losing the physical card is one of the most common reasons people end up repeating doses unnecessarily.
Combination vaccines and getting both at once
Two newer pentavalent vaccines, Penbraya and Penmenvy, combine MenACWY and MenB coverage into a single product for people ages 10 to 25, according to the FDA’s approval page. They’re designed for situations where a patient needs both types of protection at the same visit, which cuts down on the number of appointments and needle sticks a pre-college checkup otherwise requires.
- When they fit: a single visit where both MenACWY and MenB are clinically indicated.
- What they don’t replace: separate MenACWY or MenB doses for someone who only needs one type of protection.
- Recordkeeping note: clinics still document each component by product name and date, so keep or request an itemized vaccination record for future use.
What this means for your I-693 vaccination review
Meningococcal vaccination is not on the fixed list every I-693 applicant must complete, but MenACWY and MenB doses that appear on a patient’s existing immunization record are reviewed and documented as part of the overall vaccination requirements for immigration medical exams. If you already have MenACWY or MenB doses recorded elsewhere, please bring that documentation to your appointment so the civil surgeon can transcribe it accurately onto Form I-693.
If records are missing or incomplete, a civil surgeon can administer the needed doses during the same visit, which avoids a second appointment. Immigrationmedicalexams specializes exclusively in USCIS Form I-693 exams, with no primary care or urgent care visits mixed in, standard 3-day and 2-day expedited processing, and 24/7 online scheduling for applicants across Southern California.
Balancing population protection with individual choice
MenACWY exists because serogroups A, C, W, and Y cause disease broadly enough to justify a routine, universal recommendation. MenB is different by design: incidence is lower overall, but the risk concentrates sharply in specific settings such as dorms, close social contact, and certain medical conditions, which is exactly why CDC built a conversation into the recommendation instead of a mandate.
The practical order that serves most families well: confirm the MenACWY booster happened at 16, then raise MenB explicitly at the pre-college physical rather than waiting for a school to ask about it.
— ImmigrationMedicalExams Medical Team
Getting your vaccine records in order before your immigration exam
We specialize exclusively in USCIS Form I-693 immigration medical exams and vaccination review, with no primary care, urgent care, or sick visits mixed into the schedule, so your appointment stays focused on getting your form completed correctly.
Whether you need a missing MenACWY booster, a MenB discussion, or documentation transcribed from an outside provider, our civil surgeons handle it during the same visit that completes your medical exam.
- Processing options with different turnaround times to accommodate applicants’ needs.
- On-site vaccinations and titer testing to fill gaps in your immunization history.
- Online scheduling available for appointment booking.
Book your USCIS immigration medical exam or check pricing and available packages to get started.
This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.
Sources
- Meningococcal Vaccine Recommendations | CDC
- FDA: Penbraya vaccine information
- University-Based Outbreaks of Meningococcal Disease Caused by Serogroup B, United States, 2013–2018
FAQ
Should I get MenACWY or MenB, or both?
Most adolescents need MenACWY routinely at 11 to 12 with a booster at 16, since it protects against four of the five common serogroups. MenB is a separate decision made with a clinician, often centered on college housing plans or specific medical risk factors, and getting one vaccine does not cover you for the other.
What is the meningitis vaccine called in the USA?
There isn’t a single “meningitis vaccine”: MenACWY products in the U.S. include Menactra, Menveo, and MenQuadfi, while MenB is available as Bexsero or Trumenba. Two newer combination vaccines, Penbraya and Penmenvy, cover both sets of serogroups in one shot for people ages 10 to 25.
Does the meningitis shot hurt more than the flu shot?
Both MenACWY and MenB typically cause arm soreness, mild fatigue, and sometimes a low fever for a day or two, similar to what many people experience after a flu shot. Reactions are generally mild and resolve within a few days without treatment.
Why don’t adults get the meningitis vaccine routinely?
Meningococcal disease risk concentrates most heavily in adolescents and young adults, particularly those in dorm-style housing, which is why routine recommendations focus on that age group. Adults with specific risk factors, such as asplenia, complement deficiency, or travel to endemic regions, may still need MenACWY or MenB regardless of age.